Edesa Biotech, Inc.
EDSA
$4.72
-$0.01-0.21%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 42.43% | 24.86% | 18.71% | 2.67% | -16.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 126.94% | 70.09% | 18.40% | 12.78% | -23.08% |
| Operating Income | -126.94% | -70.09% | -18.40% | -12.78% | 23.08% |
| Income Before Tax | -138.26% | -78.91% | -27.95% | -16.46% | 14.57% |
| Income Tax Expenses | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Earnings from Continuing Operations | -138.24% | -78.90% | -27.94% | -16.46% | 14.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -138.24% | -78.90% | -27.94% | -16.46% | 14.56% |
| EBIT | -126.94% | -70.09% | -18.40% | -12.78% | 23.08% |
| EBITDA | -130.26% | -72.86% | -20.09% | -14.11% | 23.18% |
| EPS Basic | -27.35% | 16.06% | 39.02% | 30.27% | 39.77% |
| Normalized Basic EPS | -16.81% | 19.88% | 40.10% | 33.41% | 36.75% |
| EPS Diluted | -27.35% | 16.06% | 39.02% | 30.27% | 39.77% |
| Normalized Diluted EPS | -16.81% | 19.88% | 40.10% | 33.41% | 36.75% |
| Average Basic Shares Outstanding | 72.16% | 102.32% | 110.31% | 77.70% | 50.53% |
| Average Diluted Shares Outstanding | 72.16% | 102.32% | 110.31% | 77.70% | 50.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |